

Claims

What is claimed is:

1. An antibody against a fusion polypeptide comprising a histidine portion.
2. The antibody according to claim 1, characterized in that it is polyclonal.
3. The antibody according to claim 1, characterized in that it is monoclonal.
4. The antibody according to claim 3, characterized in that it is deposited under ACC 2207 with DSM [German-type culture collection for microorganisms].
5. A process for the preparation of an antibody according to any one of claims 1 to 4, characterized in that an animal is immunized with a histidine fusion polypeptide, and (a) polyclonal antibodies are obtained from the serum of the animal, or (b) monoclonal antibodies are obtained after the fusion of animal's spleen cells with myeloma cells.
6. The process according to claim 5, characterized in that a mixture of histidine fusion polypeptides is used for immunization.
7. Use of an antibody according to any one of claims 1 to 4 in a detection method for a fusion polypeptide comprising a histidine portion.
8. Use according to claim 7, wherein the detection method is a Western blot, an ELISA, an immunofluorescence or an immunoprecipitation.

**New Claims Filed During
Chapter II Procedure on April 11, 1997**

1. An antibody against a fusion polypeptide comprising a histidine portion, wherein the antibody is directed against the histidine portion and the latter comprises 6-18 histidine residues.
2. The antibody according to claim 1, characterized in that it is polyclonal.
3. The antibody according to claim 1, characterized in that it is monoclonal.
4. The antibody according to claim 3, characterized in that it is deposited under ACC 2207 with DSM (German-type culture collection for microorganisms).
5. A process for the preparation of an antibody according to any one of claims 1-4, characterized in that an animal is immunized with a histidine fusion polypeptide and
 - (a) polyclonal antibodies are obtained from the serum of the animal,or
 - (b) monoclonal antibodies are obtained after the fusion of animal's spleen cells with myeloma cells.
6. The process according to claim 5, characterized in that a mixture of histidine fusion polypeptides is used for immunization.
7. Use of an antibody according to any one of claims 1 to 4 in a detection method for a fusion polypeptide comprising a histidine portion.
8. Use according to claim 7, wherein the detection method is a Western blot, an ELISA, an immunofluorescence or an immunoprecipitation.